aezs 124 has been researched along with Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchholz, S; Halmos, G; Hohla, F; Ortmann, O; Papadia, A; Rick, F; Schally, AV; Seitz, S; Szalontay, L; Szepeshazi, K; Treszl, A | 1 |
| Buchholz, S; Hohla, F; Jayakumar, AR; Köster, F; Ortmann, O; Papadia, A; Rick, FG; Schally, AV; Seitz, S; Szalontay, L; Treszl, A; Weber, F | 1 |
2 other study(ies) available for aezs 124 and Breast Cancer
| Article | Year |
|---|---|
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Topics: 2-Hydroxyphenethylamine; Aniline Compounds; Animals; Antineoplastic Agents; Breast Neoplasms; Carboxylesterase; Doxorubicin; Drug Delivery Systems; Drug Stability; Female; Humans; Hydrolysis; Mice; Mice, Nude; Somatostatin; Xenograft Model Antitumor Assays | 2009 |
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Topics: 2-Hydroxyphenethylamine; Aniline Compounds; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Nucleus; Doxorubicin; Female; Humans; Mice; Mice, Nude; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Somatostatin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |